Profile
| Metric | Value |
|---|---|
| Full Name | Moderna, Inc. |
| Ticker | NASDAQ: MRNA |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Country | United States |
| IPO | |
| Indexes | |
| Website | modernatx.com |
| Employees | 5,800 |
Key Metrics
| Metric | Date | Value |
|---|---|---|
| Price | $36.35 | |
| Price, 1D Change | +7.42% | |
| Market Cap | $14B | |
| - | ||
| PE Ratio | - | |
| Beta | 1.33 | |
| Revenue | $3B | |
| Revenue, 1Y Change | -52.69% | |
| EPS | -$9.27 | |
| EPS, 1Y Change | +24.85% |
Chart
Add series to chart(max: 6)
Series
SUGGESTED SERIES
Events
| Metric | Date | Value |
|---|---|---|
| Next Earnings | ||
| Last Qtr. Earnings | ||
| Last Ann. Earnings | ||
| Last Ex-Dividend | N/A | N/A |
| Next Ex-Dividend | N/A | N/A |
| Last Split | N/A | N/A |
| Next Split | N/A | N/A |
| Last Ticker Change | N/A | N/A |
| Next Ticker Change | N/A | N/A |
🔒 Log In To Unlock Full Data
Estimates
| Metric | Date | Value |
|---|---|---|
| EPS | -$9.27 | |
| EPS Estimate | -$8.08 | |
| EPS Est. Change | +12.84% | |
| Revenue | $3.24B | |
| Revenue Estimate | $1.90B | |
| Revenue Est. Change | -41.39% | |
| Current Price | $36.35 | |
| Price Target | - | $28.00 |
| Price Tgt. Change | - | -22.97% |
🔒 Log In To Unlock Full Data
EPS
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| -$12.46 | -$12.34 | +0.96% | |
| -$9.15 | -$9.27 | -1.30% | |
| -$8.08 | N/A | +12.84% | |
| -$6.94 | N/A | +25.11% |
Revenue
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $6.05B | $6.84B | +13.13% | |
| $3.22B | $3.24B | +0.58% | |
| $1.90B | N/A | -41.39% | |
| $1.95B | N/A | -39.69% |
🔒 Log In To Unlock Full Data
Performance
| Metric | Date | Value |
|---|---|---|
| Price, 1Y | +3.41% | |
| Price, 3Y | -81.07% | |
| Market Cap, 1Y | +4.68% | |
| Market Cap, 3Y | -80.79% | |
| Revenue, 1Y | -52.69% | |
| Revenue, 3Y | -82.43% | |
| EPS, 1Y | +24.85% | |
| EPS, 3Y | -132.76% |
🔒 Log In To Unlock Full Data
Technical Indicators
| Metric | Date | Value |
|---|---|---|
| Current Price | $36.35 | |
| SMA 200 | $27.42 | |
| SMA 200 vs Price | -24.55% | |
| SMA 50 | $28.17 | |
| SMA 50 vs Price | -22.50% | |
| Beta | 1.33 | |
| ATR | $1.82 | |
| 14-Day RSI | 59.77 | |
| 10-Day Volatility | 74.80% | |
| 1-Year Volatility | 65.37% |
Dividends
| Metric | Date | Value |
|---|---|---|
| N/A | - | |
| Upcoming | N/A | N/A |
| - | ||
| - | ||
| Dividends Paid | $0.00 | |
| Payout Ratio | 0.00% |
🔒 Log In To Unlock Full Data
Income & Profitability
| Metric | Date | Value |
|---|---|---|
| Revenue | $3.24B | |
| EPS | -$9.27 | |
| Gross Profit | $1.77B | |
| Gross Margin | 54.76% | |
| Operating Profit | -$3.95B | |
| Operating Margin | -121.91% | |
| Net Income | -$3.56B | |
| Net Margin | -110.04% | |
| EBITDA | -$3.76B |
🔒 Log In To Unlock Full Data
Financial Health
| Metric | Date | Value |
|---|---|---|
| Debt To Equity | 0.00 | |
| Current Ratio | 3.67 | |
| Quick Ratio | 3.62 | |
| Interest Coverage | - | |
| F-Score | 3 | |
| Altman Z-Score | 3.43 |
Valuations
| Metric | Date | Value |
|---|---|---|
| PE Ratio | - | |
| PS Ratio | 6.36 | |
| PB Ratio | 1.52 | |
| EV/EBITDA | -3.20 | |
| Enterprise Value | N/A | - |
Balance Sheet
| Metric | Date | Value |
|---|---|---|
| Book Value | $10.90B | |
| Cash & Equivalents | $1.93B | |
| Total Assets | $14.14B | |
| Current Assets | $8.10B | |
| Total Liabilities | $3.24B | |
| Current Liabilities | $2.21B | |
| Total Debt | $747.00M | |
| Short Term Debt | $37.00M | |
| Accounts Payable | $405.00M |
Expenses
| Metric | Date | Value |
|---|---|---|
| Total Expenses | $7.18B | |
| Operating Expenses | $5.72B | |
| Cost Of Goods Sold | $1.46B | |
| SG&A | $1.17B | |
| D&A | $189.00M | |
| Interest Expense | $0.00 | |
| Income Tax | -$46.00M |
Cash Flow
| Metric | Date | Value |
|---|---|---|
| CFO | -$3.00B | |
| CFI | $1.95B | |
| CFF | $56.00M | |
| Capex | $1.05B | |
| Free Cash Flow | -$4.06B |
Recent analyst updates
| Metric | Date | Value |
|---|---|---|
| Morgan Stanley | → | |
| Jefferies | ||
| RBC Capital | → | |
| Piper Sandler | → | |
| Leerink Partners | → | |
| B of A Securities | → | |
| Barclays | → | |
| UBS | → | |
| JP Morgan | → | |
| Citigroup | → |
Analyst sentiment
Institutional ownership
Screeners with MRNA
Data Sources & References
- MRNA Official Website www.modernatx.com
- Most Recent Quarterly Report (10-Q) www.sec.gov/Archives/edgar/data/1682852/000168285225000075/0001682852-25-000075-index.htm
- Most Recent Annual Report (10-K) www.sec.gov/Archives/edgar/data/1682852/000168285225000022/0001682852-25-000022-index.htm
- List of S&P 500 Companies www.spglobal.com/spdji/en/indices/equity/sp-500/#overview
- MRNA Profile on Yahoo Finance finance.yahoo.com/quote/MRNA
- MRNA Profile on NASDAQ.com www.nasdaq.com/market-activity/stocks/mrna
FAQ
What is the ticker symbol for Moderna, Inc.?
The ticker symbol for Moderna, Inc. is NASDAQ:MRNA
Does Moderna, Inc. pay dividends?
No, Moderna, Inc. does not pay dividends
What sector is Moderna, Inc. in?
Moderna, Inc. is in the Healthcare sector
What industry is Moderna, Inc. in?
Moderna, Inc. is in the Biotechnology industry
What country is Moderna, Inc. based in?
Moderna, Inc. is headquartered in United States
When did Moderna, Inc. go public?
Moderna, Inc. initial public offering (IPO) was on December 7, 2018
Is Moderna, Inc. in the S&P 500?
Yes, Moderna, Inc. is included in the S&P 500 index
Is Moderna, Inc. in the NASDAQ 100?
No, Moderna, Inc. is not included in the NASDAQ 100 index
Is Moderna, Inc. in the Dow Jones?
No, Moderna, Inc. is not included in the Dow Jones index
When was Moderna, Inc. last earnings report?
Moderna, Inc.'s most recent earnings report was on November 6, 2025
When does Moderna, Inc. report earnings?
The next expected earnings date for Moderna, Inc. is February 13, 2026